Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease, often based on type 2 inflammation. Dupilumab and omalizumab are the currently approved biologics for the treatment of patients with severe CRSwNP without sufficient response to standard therapy with topical nasal steroids and/or post-endonasal surgery. After we have already given appropriate advice for dupilumab in a previous publication, the aim of the present paper is to standardise patient information and education prior to the therapy with omalizumab.Methods Based on the current state of knowledge on the immunology of CRSwNP and on the desired and possible adverse effects of omalizumab, recommendations for patient information are developed.Results Based on the international literature, current expert information and experience from practical use and current pharmacovigilance data, an expert panel developed recommendations for patient information and education on the use of omalizumab in CRSwNP and based on this, a patient information and education form was developed.Conclusion Patient information and consent are recommended prior to the prescription or administration of all biologics, thus including omalizumab. This position paper contains important information on practical implementation and a proposal for a patient information sheet.     «

Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease, often based on type 2 inflammation. Dupilumab and omalizumab are the currently approved biologics for the treatment of patients with severe CRSwNP without sufficient response to standard therapy with topical nasal steroids and/or post-endonasal surgery. After we have already given appropriate advice for dupilumab in a previous publication, the aim of the present paper is to standardise patient...     »